Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gilotrif for Advanced Penile Squamous Cell Carcinoma
NCT02541903Phase 2Terminated
- Sponsor
- University of Alabama at Birmingham
- Start
- Oct 2015
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of afatinib in penile squamous cell carcinoma (PSCC), sponsored by University of Alabama at Birmingham. Primary endpoint: Number of Participants With Progression Free Survival at 6 Months. Started Oct 2015; status: terminated.
02
Drugs
afatinib
03
Conditions
penile squamous cell carcinoma (PSCC)
Beyond the preview
Go deeper on NCT02541903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02541903.